Efficacy of combination therapy of DPP-4 inhibitor and alpha glucosidase inhibitor in insurin treaaed type 2 diabetes.
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000011815
- Lead Sponsor
- ational Center for Global Health and Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with severe liver dysfunction and renal dysfunction
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CGM results and the values of markers for glycemic control
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the synergistic effects of DPP-4 and alpha glucosidase inhibitors in type 2 diabetes management?
How does combination therapy with DPP-4 and alpha glucosidase inhibitors compare to standard insulin regimens in glycemic control for type 2 diabetes patients?
Which biomarkers are associated with improved outcomes in type 2 diabetes patients receiving DPP-4 and alpha glucosidase inhibitor combination therapy?
What are the potential adverse events and management strategies for DPP-4 and alpha glucosidase inhibitor combination therapy in insulin-treated type 2 diabetes?
Are there alternative combination approaches involving DPP-4 inhibitors that show promise in managing insulin-resistant type 2 diabetes compared to alpha glucosidase inhibitors?